Merck KGaA to triple its ADC manufacturing capacity in St. Louis The German science and technology group Merck KGaA has announced a € 70 million expansion of its antibody-drug conjugates (ADC) manufacturing capabilities and capacity at its Bioconjugation Center of Excellence facility in St. Louis, Missouri, USA. This investment…..
Vivet Therapeutics receives €4.9 million to advance development of a gene therapy for the treatment of cerebrotendinous xanthomatosis Funding from French Government as part of the France Health Innovation Plan 2030 Vivet Therapeutics, a French clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited metabolic disorders,…..
AiCuris and the German Center for Infection Research (DZIF) sign Collaboration and License Option Agreement ©DZIF AiCuris Anti-infective Cures AG and the German Center for Infection Research (DZIF) have signed a collaboration and license option agreement to identify novel targets for antiviral therapy and to discover new active agents for…..
Using artificial intelligence to discover therapeutic antibodies Former EMBL staff scientist founds a start-up – DenovAI – for broader, faster and cheaper antibody discovery using advanced machine learning and computational biophysics. The EMBL scientists who developed the AI-driven technology to design proteins that DenovAI will harness. From left to right:…..
Clean Cells opens new production suites close to Nantes Clean Cells, part of the Clean Biologics group, a French provider of biopharmaceutical product quality control services and manufacturer of starting materials, has launched operations in its new production suites, located in the new facility opened in January 2023, in Montaigu-Vendée,…..
DREAMS: a new Horizon Europe project combining AI and stem cells for the treatment of neuromuscular diseases [caption id="attachment_11533" align="aligncenter" width="270"] ©ISTEM[/caption] In a groundbreaking endeavour set to span five years, the DREAMS consortium is paving the way for a novel approach to treating neuromuscular diseases. This transformative project merges…..
Genethon Using AI to Improve Effectiveness of Gene Therapies and Patient Access CEO Frederic Revah discusses how Artificial Intelligence is creating next-generation gene therapy vectors and reducing bioproduction costs in the latest issue of Genethon’s Newsletter Genethon, a unique non-profit gene therapy R&D organization founded by the French Muscular Dystrophy…..
Broken String Biosciences Closes $15M Series A Funding Round Broken String Biosciences, a UK-based genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, has closed a $15 million Series A investment round, co-led by Illumina Ventures and Mérieux Equity…..
AlveoGene to develop inhaled gene therapies for rare respiratory diseases AlveoGene is a new gene therapy company created and funded by Oxford Science Enterprises, Harrington Discovery Institute and Old College Capital in partnership with six leading scientists from the UK Respiratory Gene Therapy Consortium (GTC). The Oxford-based company will use…..
MaaT Pharma and Skyepharma Complete Construction of Europe’s Largest Manufacturing Facility for Microbiome Ecosystem Therapies • Major milestone achieved with new state-of-the-art microbiome facility spanning over 1600 m², completed within the 12-month timeframe, further enhancing bioproduction capabilities and contributing to the ecosystem in France and Europe. • MaaT Pharma is…..
- 1
- 2
- 3
...
- 21
- Page Suivante
